Remarkably, α-helical D-peptides designed in silico were reported to block the binding of the SARS-CoV-2 spike protein receptor-binding domain (RBD) to the human angiotensin-converting enzyme 2 (ACE2), the molecule that mediates the virus internalization into human cells, thus leading to the inhibition of viral infection in vitro (Valiente et al., 2021). Here, ACE2 is linked to viral infectious disease.